Table 3 Comparison of the clinical manifestations according to the genotype of MFGE8 gene in patients with SLE.

From: Polymorphisms of MFGE8 are associated with susceptibility and clinical manifestations through gene expression modulation in Koreans with systemic lupus erythematosus

Characteristicsrs4945 C > Ars1878326 C > Ars1878327 G > Ars2271715 C > Trs3743388 G > C
CC
n = 235
(83.9%)
CA, AA
n = 45
(16.1%)
CC
n = 106
(37.9%)
CA, AA
n = 174
(62.1%)
CC
n = 99
(35.4%)
GG, AA
n = 181
(64.6%)
CC
n = 63
(22.5%)
CT, TT
n = 217
(77.5%)
GG
n = 99
(35.4%)
GG, CC
n = 181
(64.6%)
Alopecia36 (15.3)4 (8.9)20 (18.9)20 (11.5)20 (20.2)20 (11.0)*11 (17.5)29 (13.4)12 (17.6)28 (13.2)
Arthritis66 (28.0)8 (17.8)34 (32.0)40 (23.0)30 (30.3)44 (24.3)14 (22.3)60 (27.6)18 (26.5)56 (26.4)
Renal disease45 (19.1)12 (26.7)24 (22.6)33 (19.0)22 (22.3)35 (19.3)23 (36.5)34 (15.7)***24 (35.3)33 (15.6)***
Platelet, x10³/μL222.9 ± 83.3222.3 ± 66.1211.7 ± 85.7229.5 ± 77.0210.1 ± 86.2229.7 ± 76.9221.8 ± 70.0223.0 ± 83.8215.1 ± 67.6225.2 ± 84.5
ESR, mm/h22.6 ± 19.628.1 ± 29.3**27.2 ± 23.521.2 ± 20.026.5 ± 23.221.8 ± 20.426.0 ± 21.222.8 ± 21.625.8 ± 22.122.8 ± 21.3
CRP, mg/dL0.84 ± 2.760.77 ± 2.051.33 ± 3.40.52 ± 1.5***1.42 ± 4.00.51 ± 1.5***0.80 ± 2.10.84 ± 2.81.12 ± 3.00.74 ± 2.5
Complement3, mg/dL95.9 ± 37.489.2 ± 31.292.2 ± 40.495.7 ± 34.092.7 ± 42.096.0 ± 33.2*85.9 ± 34.097.4 ± 36.986.8 ± 31.497.3 ± 37.6
Complement4, mg/dL20.7 ± 11.321.6 ± 12.819.3 ± 12.621.7 ± 10.819.0 ± 12.721.8 ± 10.818.0 ± 9.621.6 ± 12.019.4 ± 10.221.3 ± 12.0
Anti-dsDNA Ab, IU/mL10.2 ± 18.47.1 ± 11.212.6 ± 21.58.0 ± 14.3***12.2 ± 21.38.4 ± 14.911.4 ± 20.59.3 ± 16.511.4 ± 21.49.2 ± 16.1*
SLEDAI, > 654 (23.0)9 (20.0)36 (34.0)27 (15.5)***34 (34.4)29 (16.0)***15 (23.8)48 (22.1)18 (26.5)45 (21.2)
Glucocorticoid cumulative dose, g7.0 ± 9.85.3 ± 8.78.6 ± 11.25.7 ± 8.4**8.0 ± 10.96.0 ± 8.810.0 ± 13.25.8 ± 8.1***11.0 ± 13.15.4 ± 7.8***
Azathioprine37 (15.7)9 (20.0)14 (13.2)32 (18.4)12 (12.1)34 (18.8)11 (17.5)35 (16.1)13 (19.1)33 (15.6)
Cyclophosphamide20 (8.5)3 (6.7)9 (8.5)14 (8.0)6 (6.1)17 (9.4)9 (14.3)14 (6.5)*11 (16.2)12 (5.7)**
Mycophenolate mofetil23 (9.8)4 (8.9)13 (12.3)14 (8.0)9 (9.0)18 (9.9)12 (19.0)15 (6.9)*13 (19.114 (6.6)**
Methotrexate39 (16.6)6 (13.4)21 (19.8)24 (13.8)18 (18.2)27 (14.9)8 (12.7)37 (17.0)8 (11.8)37 (17.5)
  1. Results are shown as n (%) or mean ± SD. Each p value calculated using linear regression analysis and Mann-Whitney U test. Values p < 0.05 were considered statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001. MFGE8: milk fat globule epidermal growth factor 8; SLE: systemic lupus erythematosus; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; dsDNA: double strand deoxynucleic acid; Ab: antibody; SLEDAI: systemic lupus erythematosus disease activity index; SD: standard deviation.